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Sir,
There has been a paradigm shift in mediastinal staging algorithms in
non-small cell lung cancer over the last decade in the United Kingdom
(UK). This has seen endoscopic nodal staging (predominantly endo-
bronchial ultrasound, EBUS) almost replace surgical staging (predomi-
nantly mediastinoscopy) as the pathological staging procedure of first
choice. An explosion of EBUS services has facilitated this, with 45% of
National Health Service Trusts currently delivering EBUS procedures
almost exclusively by chest physicians (Cusworth et al, 2015). However,
performance measures for this pivotal procedure in lung cancer
management are not widely agreed or published. We believe that there
is an urgent need for systematic data collection by all EBUS services to
standardise practice and assess outcomes; a view also held by members of
a UK expert round table discussion for improving lung cancer outcomes
and an EBUS review article (Sethi et al, 2013; Rintoul et al, 2015). The
performance measures for EBUS in lung cancer depend on whether the
procedure is done purely for pathological diagnosis (diagnostic EBUS) or
for mediastinal nodal staging (systematic staging EBUS). The drive for
systematic nodal staging, in patients with potentially early stage disease,
is to improve the accuracy of staging (and not be reliant on radiological
staging), thereby improving patient selection for the most appropriate
treatment and hopefully improve survival. In line with this, systematic
staging EBUS has been shown to improve survival in lung cancer patients
vs non-endoscopic staging in post hoc analysis (Navani et al, 2015).
When considering the performance measures for systematic staging
EBUS, there are some important discussion points as follows:
HOW IS SYSTEMATIC STAGING EBUS PERFORMED?
There is a clear need for standardisation of EBUS practice across all
centres to ensure optimal outcomes. For staging EBUS, a systematic
examination of the mediastinum is recommended beginning with an
examination of the contralateral N3 nodal stations followed by N2
stations and finally N1 lymph nodes when required. Any lymph node
measuring X5mm is sampled aiming for a minimum of three N2/3
lymph node stations sampled per procedure. This technique has
demonstrated excellent sensitivity and negative predictive values
(NPV) from expert centres (Herth et al, 2008; Yasufuku et al, 2011;
Navani et al, 2015). This technique needs to be distinguished from a
‘targeted’ procedure whereby only abnormal lymph nodes on pre-
procedure radiology are imaged and sampled. This technique is more
allied to diagnostic EBUS although it is acknowledged that this often
yields staging information sufficient to determine treatment. In the
majority of cases, a systematic staging EBUS will require a longer
procedure time compared with standard flexible bronchoscopy. The
optimal sedation practice for systematic staging EBUS is debated. In the
UK, the standard practice remains physician-led conscious sedation with
a combination of midazolam and an opiate such as fentanyl or alfentanil.
Some expert centres use anaesthetist-led deep sedation, for example,
using propofol. The use of propofol and anaesthetic-led administration
in flexible bronchoscopy has been shown to improve patient satisfaction
and tolerance through reduction in cough, pain and discomfort without
affecting complications such as hypoxia. This evidence is summarised in
a recent review article (Jose et al, 2013). Anaesthetic-led sedation in
staging EBUS, where there may be additional benefits of allowing more
extensive sonographic assessment and a higher volume of nodal
sampling, has not been studied. Ultimately, the effectiveness of a
sedation strategy will be reflected in the performance measures of that
service. Failure to achieve the benchmarks set out in this document may
prompt reconsideration of the sedation practice and could provide an
area for potential adjustment to drive improvements.
HOW SHOULD PERFORMANCE BE MEASURED FOR
SYSTEMATIC STAGING EBUS?
The most important performance measures of staging EBUS are
sensitivity and NPV, both influenced by the false-negative rate.
Specificity and positive predictive value are not discriminatory and
widely reported as 100% in meta-analysis and systematic reviews
totalling several thousand patients (Adams et al, 2009; Gu et al, 2009;
Varela-Lema et al, 2009). Although it is not common place for positive
N2/3 disease identified by staging EBUS to undergo surgical verification,
false positives are considered extremely rare and confined to case reports
such as carcinoma-in situ at the bronchial puncture site (Sanz-Santos
et al, 2012). For sensitivity and NPV calculations, the identification of
patients with N2/3 metastases missed by systematic staging EBUS is
pivotal. This requires a thorough review of any subsequent pathological
nodal sampling (e.g., mediastinoscopy or intra-operative lymph node
sampling) and a minimum of 6 months clinical–radiological follow up.
The denominator for sensitivity calculations should be the overall
number of patients with N2/3 nodal metastases (even in those lymph
node stations inaccessible with EBUS). This provides a far more accurate
assessment of the ability of EBUS to stage the mediastinum than a per
lymph node denominator. The British Thoracic Society quality standard
for systematic staging EBUS sensitivity is488% but both sensitivity and
NPV have been shown to be dependent upon the overall prevalence of
N2/3 metastases in the population undergoing EBUS. For example,
although the American College of Chest Physicians (ACCP) report a
sensitivity of 89% and NPV of 91% for staging EBUS in a large meta-
analysis, they also demonstrate that sensitivity is positively correlated
with the prevalence of N2/3 disease within the patients undergoing
EBUS, whereas NPV is negatively correlated (Silvestri et al, 2013)
(Table 1). This could reflect a biological difference in the nodes in higher
Table 1. Sensitivity and negative predictive value of
endobronchial ultrasound (EBUS) for nodal staging in lung
cancer (Results from ACCP meta-analysis and recommended
minimum standards) based on the prevalence of N2/3 disease
Sensitivity
Negative predictive
value
N2/3
prevalence
(%)
ACCP
meta-
analysis
(%)
Minimum
standard
(%)
ACCP
meta-
analysis
(%)
Minimum
standard
(%)
480 96 490 83 480
60–80 91 488 83 480
40–60 87 485 89 485
20–40 87 480 95 490
o20 78 475 96 492
Abbreviation: ACCP¼American College of Chest Physicians. Adapted from the ACCP Lung
Cancer Staging Guidelines meta-analysis of EBUS (Silvestri et al, 2013).
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prevalence populations vs lower prevalence populations (macroscopic
nodal involvement in larger FDG-avid nodes vs microscopic metastases
in small non-avid nodes). It is therefore crucial that the prevalence of
N2/3 metastases is presented alongside the sensitivity and NPV for all
systematic staging EBUS centres. Furthermore, the ACCP staging
guidelines also describe appropriate patient selection for pathological
nodal staging by separating patients into four groups (groups A–D,
excluding those with distant disease) based on the index staging
computed tomography (CT) scan of the thorax. These groups are also
based on the differing prevalence of N2/3 disease (Table 2) and can
therefore help to define standards for staging EBUS within these groups,
thereby not using a single standard for all staging EBUS.
Taking all these considerations into account, we propose the following
data fields should be recorded for all staging EBUS centres:
 EBUS procedure indication.
 Sedation strategy (physician-led vs anaesthetic-led; conscious sedation
vs deep sedation).
 Type of EBUS procedure (diagnostic or systematic staging).
 ACCP group based on index staging CT of the thorax.
 Nodal stations sampled.
 Nodal staging based on EBUS pathology (N0–N3).
 Final nodal staging (N0–N3).
 Method of confirmation of final nodal staging (subsequent patholo-
gical sampling or 6 months clinical–radiological follow up).
 Complications; in line with definitions provided by the British
Thoracic Society Guidelines for Bronchoscopy (Du Rand et al, 2013).
We propose these data are used to report:
 Number of N2/3 lymph node stations sampled per procedure.
 Prevalence of N2/3 disease in patients undergoing systematic staging
EBUS.
 Sensitivity of systematic staging EBUS to detect N2/3 disease, stratified
by ACCP group.
 NPV for exclusion of N2/3 disease by systematic staging EBUS,
stratified by ACCP group.
This detailed breakdown of EBUS performance may identify specific
patient groups where improvements may be needed that may otherwise
not have been apparent, and provides information on patient selection as
well as performance. Furthermore, we propose a set of minimum
standards for sensitivity and negative predictive value based on N2/3
prevalence that we believe is an achievable benchmark for staging EBUS
centres to be working (Table 1).
This statement has focused on EBUS as the endoscopic technique of
choice for mediastinal staging, as this technique is widely available across
the UK. However, we also acknowledge that combining endoscopic
ultrasound from the oesophagus with EBUS (EBUS–EUS) has a number
of potential benefits (Annema et al, 2010). In addition to sampling
mediastinal nodes by EBUS, EUS provides a different approach to some
lymph node groups (2L, 4L and 7) as well as access to the inferior
mediastinal stations (8 and 9) that are inaccessible to EBUS. Furthermore
EUS can allow access to the left adrenal gland, left lobe of the liver and
coeliac lymph nodes providing extra thoracic staging in the same sitting
for selected cases. While there are implications in terms of resources to
implement this on a wider scale in the UK, EBUS–EUS is advocated
as the endoscopic staging tool of choice in the European guidelines
(De Leyn et al, 2014). Chest physicians using the EBUS scope in the
oesophagus (EUS-B) could address some of these resource issues and
should be subjected to the same rigorous assessment of performance
described here.
In conclusion, we advocate all services collect and publish standar-
dised outcome data with the ultimate goal of agreed national standards
for evaluation and commissioning. Furthermore, we advocate that
accreditation is considered for centres performing staging EBUS-TBNA
using standards defined by a relevant professional group such as the
British Thoracic Society or the Royal College of Physicians. This will help
to ensure that standards are maintained for this important staging
investigation.
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